Skip to main content
Josef Coresh on Muck Rack

Josef Coresh

As seen in: Nature, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, Medscape, The American Journal of Human Genetics, Nephrology Dialysis Transplantation, The Lancet, Annals of Internal Medicine, Diabetes Care Magazine, Texas Medical Center and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Josef

Contact Josef, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Measured and Estimated Glomerular Filtration Rates and Risk of Adverse Health Outcomes

|
By Edouard L. Fu, Morgan E. Grams, Josef Coresh, Arvid Sjölander, Anne-Laure Faucon, Michelle M. Estrella, Friedo W. Dekker, Michael G. Shlipak, Lesley A Inker, Andrew S. Levey, Juan-Jesus Carrero, Antoine Créon
| JAMA: Journal of the American Medical Association Verified
Measured and Estimated Glomerular Filtration Rates and Risk of Adverse Health Outcomes Supplement 1. eMethods. Additional Details on Iohexol Plasma Clearance eTable 1. Definition of Study Covariates and Outcomes eTable 2. Baseline Characteristics of Persons Undergoing mGFR Testing Using Plasma Clearance of Iohexol in Stockholm With Simultaneous Creatinine and Cystatin C Testing During 2011-2021, With Versus Without Missing Data of UACR and Body Mass Index eTable 3.
Open in Who Shared Issue with article?

Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals

|
By Brendon L Neuen, Rupert W. Major, Morgan E. Grams, Yingying Sang, Josef Coresh, Shoshana H. Ballew, Aditya Surapaneni, Natalia Alencar de Pinho, Johan Ärnlöv, Clare Arnott, Samira Bell, Jarett Berry, Hermann Brenner, Elizabeth L Ciemins, Alexander Chang, Mary Cushman, James de Lemos, Juan Miguel Diaz-Tocados, Alfredo E. Farjat, Robert Fletcher, Ron T Gansevoort, Hiddo J. L. Heerspink, William G Herrington, Chuan Hong, Shih-Jen Hwang, Simerjot K Jassal, Philip A. Kalra, Ronit Katz, Sadiya Khan, Csaba P. Kovesdy, Florian Kronenberg, Jennifer Lees, Donald M. Lloyd-Jones, José Geraldo Mill, David Naimark, Chiadi E. Ndumele, Kevan R. Polkinghorne, Bruce M. Psaty, Patrick Schloemer, Michael G. Shlipak, Prabin Shrestha, Zean Song, Natalie Staplin, Dominik Steubl, Priya Vart, Frank L. J. Visseren, Mark Woodward, Kazumasa Yamagishi, Bessie A. Young, Charumathi Sabanayagam, José M. Valdivielso
| Nature Verified
Abstract The American Heart Association’s PREVENT equations estimate risk of total cardiovascular disease (CVD), atherosclerotic CVD (ASCVD), and heart failure (HF) to guide lipid and blood pressure-lowering therapy in people ages 30 to 79 years in the United States. The SCORE2 risk algorithm is used to estimate CVD risk for similar purposes in people ages 40 and older in Europe. Neither set of equations has been comprehensively validated in global observational cohorts and randomized trials.
Open in Who Shared Issue with article?

Proteomic risk score for early prediction of kidney disease progression in individuals with APOL1 high-risk genotypes

|
By Chenyu Li, Shola Richards, Ghazal Quinn, Amin Abedini, Minyan Zhu, Tanya verma, Samer Mohandes, Rebecca Pitts, Xiazi Qiu, Taehwan Shin, Joseph Loureiro, Nancy Finkel, Aditya Surapaneni, Josef Coresh, Morgan E. Grams, Hongzhe Li, Anurag Verma, Marylyn D. Ritchie, Daniel Rader, Penn Medicine Biobank, William Dietrich, Lori L. Jennings, Katalin Susztak, Vesna Barros, Anil Karihaloo
| Nature Verified
Abstract Individuals of African ancestry carrying APOL1 (apolipoprotein L1) high-risk genotypes face a markedly increased risk of kidney failure, yet tools to identify those individuals likely to progress to chronic kidney disease are lacking. Here we profiled plasma proteomes of 851 Penn Medicine BioBank participants of African ancestry (285 males and 566 females) with APOL1 high-risk genotypes and preserved estimated glomerular filtration rate (eGFR) (≥60 ml min−1 1.73 m−2).
Open in Who Shared Issue with article?
See all 50 licensed articles (52 Total)